Abstract
Parkinson's disease (PD) is a neurodegenerative disease, however, besides the motor symptoms, such as rest tremor, hypokinesia, postural instability and rigidity, PD patients have also non-motor symptoms, namely neuropsychiatric disorders. Apart from the required motor symptoms, psychopathological symptoms are very common and include mood disorders, anxiety disorders, hallucinations, psychosis, cognitive deterioration and dementia. The underlying pathophysiological process in PD is mainly due to the loss of dopaminergic neural cells and thereby causes the shortage of nigrostriatal dopamine content in them. In addition, it may involve other neurotransmitter systems such as the noradrenergic, serotonergic, cholinergic and noradrenergic systems as well. Depression can result from any unhealthy conditions making the diagnosis a challenging task. The manifestation of depression associated with or without PD is inadequate. The co-occurrence of depression and PD often leads to the conceptual discussion on whether depressive symptoms appear before or after PD develops. This paper will discuss the conceptual mechanism of PD and depression. Keep in mind both conditions belong to two separate entities but share some similar aspects in their pathophysiology.
Keywords: Parkinson's disease, depression, neuro degeneration, Aetiology, Dopamine
1. Introduction
Parkinson's Disease (PD) is one of the major neurodegenerative diseases that commonly start during the middle age of life, even though early onset of the disease has happened [1]. Only 14–15% of cases of PD while found to be linked with genetic abnormalities, most of the PD cases are still known as sporadic, however, related to age, brain injury, pesticides, etc [2]. The major symptoms of PD are tremors, slow movement, muscle weakness and ultimately memory loss [3]. The pathology occurs due to the lack of dopamine (DA) in the substantia nigra (SN) region of the brain, as well as the presence of aggregated α-synuclein (Lewy bodies), neurofilaments and ubiquitin across the neural cell transmission pathways [7]–[9]. It has been calculated that in human when they lose 48–68% of the dopaminergic neurons at the SN and/or loss of DA content around 70–80% at the striatum occurs, PD may develop in them [10],[11].
Depression is a mental health disorder characterized by loss of interest in activities in daily life, and also loss of appetite, energy level, concentration, daily behavior, and sometimes thoughts doing suicide, also. Possible causes of PD are still unknown, but it is believed that some biological and/or social sources of distress may cause changes in certain neural circuits in the brain [4]. However, expression is not age-related and has a number of symptoms in common with PD [5]. These shared symptoms of PD and depression include tiredness, reduced energy, psychomotor retardation and a lack of facial expressions, loss of appetite, mental slowing, insomnia and difficulties in concentrating [6]. Further, lowered mood, anhedonia, and lack of interest, which can be found both in depression disorder and in PD [7]. The prevalence of depression in PD is 2 to 3 times higher than the major depressive disorder in the elderly population [8]–[11].
Figure 1. Graphical abstract.
1.1. Link between depression and Parkinson's Disease
Depression and anxiety occur with high frequency in patients with Parkinson's disease. In fact, depression has been seen in nearly 50% of PD cases [8]–[11].
Stress increases the death of dopaminergic cells and results in severe PD symptoms [12]–[15].
Dopamine can help PD and major depression disorder [16].
Loss of serotonin and dopamine can cause depression, a loss of energy and pleasure when doing any work. Furthermore, dopamine deficiency results in PD-specific symptoms, such as tremors, muscle weakness and difficulty with balance [12]–[20].
Depression can result in memory loss or confusion, which also appears to PD patients later on [21].
So far, depression has not been linked with any specific genotype of PD [22].
2. Etiology
Some studies have shown that PD constitutes to a biological risk factor for depression. Other studies conclude that depression also predisposes for PD [23],[24]. It is hypothesized that an allostatic state can developed due to depression, which leads to atrophy of nerve cells in the brain and cause neurodegenerative diseases [25]. There is also evidence that PD symptoms and its therapeutic regimen, a higher dose of levodopa, may increase the risk of depression in PD (reword sentence it doesn't make sense) There is evidence that a higher dose of levodopa may increase the risk of depression in PD [26]–[30].
The general consensus of the case histories on depression induced by dopa-agonists is to improve mood. Recent publications of the antidepressant effect of pramipexole in patients with PD have led to clinical investigations of the usefulness of pramipexole in the treatment of depression in patients without PD [31]–[33].
Several hypotheses try to provide a pathophysiological explanation for the higher prevalence of depression in PD patients. However, none have been empirically tested so far. Mayeux et al. formulated the serotonergic hypothesis in 1984 based on the findings that serotonergic activity in the cerebrospinal fluid and the brains of PD patients was lowered [34].
2.1. Biochemical Theory of Depression
The serotonergic and dopaminergic hypothesis indicates that serotonin inhibits dopamine release but eventually causes the onset of PD symptoms. At the same time, it is known that a reduced serotonergic tone is a risk factor for depression [12],[13]. Furthermore, the dopaminergic hypothesis considers depression is caused by the degeneration of the mesolimbic and mesocortical structures of the dopaminergic system. This may explain why depression may occur in patients with or without PD [14].
2.2. Genetics in PD and in Depression
Table 1. Genetic factors in PD and Depression.
| Gene(s) | PD | Depression |
| PARK2 Gene | Mutations in the parkin gene (PARK2) on chromosome 6q have been implicated in early onset PD (EOPD), commonly defined as PD with onset <50 years of age, but their role in non-motor manifestations is not well established [35] | Genotype was not associated with depression risk among probands. However, parkin mutations might be predisposed to depression prior to the onset of PD [38] |
| LRRK2 Gene | A meta-analysis of studies investigating LRRK2 rs34637584 confirmed that the minor allele carriers had significantly less cognitive impairment (p = 0.015) in people with PD [36] | Minor alleles of GBA variants rs76763715, rs421016, rs387906315 and rs80356773 were associated with more depressive symptoms in PD. |
| APOE, BDNF, CRY1 | APOE ε4 allele has been associated with more cognitive impairment in PD [37] | BDNF (rs6265) and CRY1 (rs2287161) variants have been associated with more depressive symptoms in people with PD. [38] |
Recently, a genetic abnormality behind the PD was reviewed by Chakraborty and Diwan [39]. A genome-wide association study (GWAS) with million people have identified 178 gene variants linked to major depression [40]–[42]. These types of large-scale findings help the clinicians:
to evaluate the polygenic risk scores, and
to develop new medications.
2.3. Environmental factors in PD and Depression
It was suggested that PD is linked to numerous environmental toxins for example, chemicals [43]–[45], pesticides [46] and heavy metals [47]–[49]. Ambient air pollution from traffic can also augment the chance of PD onset [50],[51]. Long-time use of illicit drugs can cause abnormal morphology in the substantia nigra [52], and produces reactive oxygen species causing dopamine neuron toxicity and death [53],[54].
Psychological factors
Negative thoughts, like sadness, helplessness and hopelessness perceived for long periods may make a person more vulnerable to depression [55].
Social isolation: Social Isolation or a lack of a supportive social network, early retirement or loss of independence can increase the depression risk, too [56].
2.4. The Link Between Depression and PD
Depression is a part of Parkinson's disease itself. PD affects the areas of the brain that produce dopamine, norepinephrine and serotonin—chemicals involved in regulating energy, mood, mood, energy, motivation, sleep and appetite [57]. For many people, the challenges of Parkinson's disease are enough to cause depression [57].
On the other hand, the pathological process of Parkinson's disease and the mood disorder, like depression and bipolar disorders, both results from the same brain cell damage beneath the substantia niagra. These cells could be affected years before the tremors are even evident. This finding means that depression may precede a formal diagnosis of PD.
2.5. Clinical Features of PD and Depression (Table 2)
Table 2. Clinical features of PD and Depression.
| Major depression | Parkinson's disease | |
| Motor phenomena |
|
|
| Other somatic complaints | Physical complaints, Muscle tension, Gastrointestinal symptoms, Sexual dysfunction | |
| Vegetative changes | Decreased energy, Fatigue, Sleep and Appetite changes | |
| Cognitive disturbances | Poor concentration, Decreased memory, Impaired problem-solving | |
2.6. Other Commonness in Depression and PD:
Long-time psychiatric disorders, like depression, anxiety may end up in motor nerve illness resulting movement disorder [58].
PD victims experience depression and/or anxiety two to five years before a Parkinson's diagnosis, indicating depression could be a part of the underlying disease process [59].
PD and depression affect the same part of the brains which is involved in thinking and emotion (SN region). Damage of SN region impacts the levels of three important neurotransmitters (dopamine, serotonin and norepinephrine) that influence mood and movement [60].
In one study [61] of late onset PD, 9.2% of patients had a history of depression at the time of a diagnosis of PD, much higher than the control cases (only 4%).
Degeneration of dopaminergic fibers has been suggested to be involved in depression [62].
There is evidence that noradrenaline may be involved in depression [63].
3. Treatment
Treatment of depression in PD patients is just as important as the treatment of PD itself because depression negatively affects cognitive performance, daily activities and quality of life [17],[18]. The treatment for mild depression is supportive psychotherapy, which may stimulate the patient to engage in personal and social activities. In cases of more severe depression, pharmacological treatment is warranted [19]. Dopamine reuptake inhibitor is the treatment of choice when it comes to depression in PD patients [19].
In the dopaminergic theory, depression is believed to be a result of the deficient self-reward mechanisms that are located in the mesocortical and mesolimbic dopaminergic structures [20]. Parkinsonism may occur occasionally during the treatment of depression in a patient who does not suffer from PD symptoms [21].
Table 3. Treatment strategies of PD and Depression [64]–[68].
| Medication | Depression | PD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4. Discussion and conclusion
Parkinson's disease is a neurological disorder that involves an imbalance when standing and walking, tremors, stiff muscles and slow movement.
Depression is a medical problem which can cause a long-lasting feelings of sadness or hopelessness.
Many people experience sadness or grief when they receive a diagnosis of a serious condition such as Parkinson's disease. In some cases, depression can occur.
Depression is a mood disorder that can affect a person's ability to carry out daily activities. About 50% of people with PD have depression at some time during their illness, and around 40% experience anxiety. This appears to be distinct from feeling sad knowing the diagnosis and prognosis of the disease.
Reduced dopamine leads to the physical symptoms of Parkinson's disease [17],[30].
Distinct diagnosis of PD and depression is challenging. Common symptoms of PD and depression include drooping eyes, having a flat expression, signs of apathy and slow speech that can occur.
The levels of cerebrospinal fluid 5-HIAA, which is a metabolite of serotonin (5-HT), are reduced in depressed patients with or without PD symptoms [69],[70].
Serotonin re-uptake inhibitors have no beneficiary effect on motor functioning but can be effective in treating depression [71]–[75].
Tricyclic antidepressants (TCAs) can be used effectively for treating a motor disability in PD [71]–[73].
Due to the overlapping symptomatology of PD and depression, it is often difficult to recognize depression as a separate entity. In fact, the partly shared pathophysiology may increase the difficulty when specifically treating mood symptoms, without influencing motor or cognitive symptoms.
Large placebo-controlled studies are necessary to further evaluate the potential efficacy of the antidepressant treatment and allow evidence-based treatment guidelines to develop.
Defects in the serotonergic neurotransmitters circuit can occur even without the involvement of dopaminergic neurons.
The pathophysiology of “depression” in patients with or without PD should be better investigated.
Altogether, it is common for a person with PD to experience symptoms of depression. It may stem from some of the same brain changes that cause the physical characteristics of PD. A doctor can help the individual in finding treatments for managing depression.
Acknowledgments
We acknowledge all our colleagues and secretaries for their help during the preparation of the manuscript and providing all the relevant information. Thanks are due to Ms. Bethany Pond, a Chemist at AllExcel, Inc. for the English corrections.
Footnotes
Author contributions: Both of the authors contributed equally to preparing this article, reading and approving the final manuscript.
Conflict of interest: Both of the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
- 1.Ray Chaudhuri K, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245. doi: 10.1016/S1474-4422(06)70373-8. [DOI] [PubMed] [Google Scholar]
- 2.Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2(1):a008888. doi: 10.1101/cshperspect.a008888. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Parkinson's Disease: Causes, Symptoms, and Treatments. Available from: https://www.nia.nih.gov/health/parkinsons-disease.
- 4.World Health Organization. Depression: Fact Sheet. 2017. Available from: http://www.who.int/mediacentre/factsheets/fs369/en.
- 5.American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR) Washington, DC: American Psychiatric Association; 2000. [DOI] [Google Scholar]
- 6.Hornykiewicz O. Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res. 1975;11(3):13–21. doi: 10.1037/e472122004-001. [DOI] [PubMed] [Google Scholar]
- 7.Jellinger K. An overview of morphological changes in Parkinson's disease. Adv Neurol. 1986;45:1–18. [PubMed] [Google Scholar]
- 8.Hantz P, Cardoc-Davies G, Cardoc-Davies T, et al. Depression in Parkinson's disease. Am J Psychiatry. 1994;151:1010–1014. doi: 10.1176/ajp.151.7.1010. [DOI] [PubMed] [Google Scholar]
- 9.Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease; a community based study. Arch Neurol. 1996;53:175–179. doi: 10.1001/archneur.1996.00550020087019. [DOI] [PubMed] [Google Scholar]
- 10.Beekman ATF, Copeland JRM, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry. 1999;174:307–311. doi: 10.1192/bjp.174.4.307. [DOI] [PubMed] [Google Scholar]
- 11.Reijnders JSAM, Ehrt U, Weber WEJ, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Movement Disord. 2008;23:183–189. doi: 10.1002/mds.21803. [DOI] [PubMed] [Google Scholar]
- 12.Mayeux R. The serotonergic hypothesis for depression in Parkinson's disease. Adv Neurol. 1990;53:163–166. [PubMed] [Google Scholar]
- 13.Van Praag HM, De Haen S. Central serotonergic metabolism and frequency of depression. Psychiatr Res. 1979;1:219–224. doi: 10.1016/0165-1781(79)90002-7. [DOI] [PubMed] [Google Scholar]
- 14.Baquero M, Martin N. Depressive symptoms in neurodegenerative diseases. World J Clin Cases. 2015;3(8):682–693. doi: 10.12998/wjcc.v3.i8.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinson's disease. Exp Neurol. 2012;233(1):79–86. doi: 10.1016/j.expneurol.2011.09.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Van Praag HM, Asnis GM, Kahn RS. Monoamines and abnormal behaviour: a multi-aminergic perspective. Br J Psychiatry. 1990;157:723–734. doi: 10.1192/bjp.157.5.723. [DOI] [PubMed] [Google Scholar]
- 17.Hobson P, Holden A, Meara J. Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire. Age Ageing. 1990;28:341–346. doi: 10.1093/ageing/28.4.341. [DOI] [PubMed] [Google Scholar]
- 18.Liu CY, Wang SJ, Fuh JL, et al. The correlation of depression with functional ability in Parkinson's disease. J Neurol. 1997;244:493–498. doi: 10.1007/s004150050131. [DOI] [PubMed] [Google Scholar]
- 19.American Psychiatric Association. Practice guideline for major depressive disorder in adults. American Psychiatric Association practice guidelines for the treatment of psychiatric disorder. Washington, DC: American Psychiatric Association; 2000. pp. 413–495. [Google Scholar]
- 20.Fibiger HC. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci. 1984;11:105–107. doi: 10.1017/S0317167100046230. [DOI] [PubMed] [Google Scholar]
- 21.Gonul AS, Aksu M. SSRI-induced parkinsonism may be an early sign of future Parkinson's disease. J Clin Psychiatry. 1999;60:410. doi: 10.4088/JCP.v60n0611d. [DOI] [PubMed] [Google Scholar]
- 22.Mayeux R, Stern Y, Cote L, et al. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology. 1984;34:642–646. doi: 10.1212/WNL.34.5.642. [DOI] [PubMed] [Google Scholar]
- 23.Schuurman AG, Van den Akker M, Ensinck KTJL, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology. 2002;58:1501–1504. doi: 10.1212/WNL.58.10.1501. [DOI] [PubMed] [Google Scholar]
- 24.Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand. 2001;104:380–386. doi: 10.1034/j.1600-0447.2001.00372.x. [DOI] [PubMed] [Google Scholar]
- 25.McEwen BS. Mood disorders and allostatic load. Biol Psychiatry. 2003;54:200–207. doi: 10.1016/S0006-3223(03)00177-X. [DOI] [PubMed] [Google Scholar]
- 26.Cole SA, Woodard JL, Juncos JL, et al. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1996;8:20–25. doi: 10.1176/jnp.8.1.20. [DOI] [PubMed] [Google Scholar]
- 27.Santamaria J, Tolosa ES, Valles A, et al. Mental depression in untreated Parkinson's disease of recent onset. Adv Neurol. 1986;45:443–446. [PubMed] [Google Scholar]
- 28.Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol Med. 2001;31:65–73. doi: 10.1017/S0033291799003141. [DOI] [PubMed] [Google Scholar]
- 29.Starkstein S, Preziosi TJ, Bolduc PL, et al. Depression in Parkinson's disease. J Nerv Ment Dis. 1990;178:27–31. doi: 10.1097/00005053-199001000-00005. [DOI] [PubMed] [Google Scholar]
- 30.Tandberg E, Larsen JP, Aarsland D, et al. Risk factors for depression in Parkinson's disease. Arch Neurol. 1997;54:625–630. doi: 10.1001/archneur.1997.00550170097020. [DOI] [PubMed] [Google Scholar]
- 31.Rektorova I, Rektor I, Bares M, et al. Pramipexole and per-golide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399–406. doi: 10.1046/j.1468-1331.2003.00612.x. [DOI] [PubMed] [Google Scholar]
- 32.Corrigan MH, Denehan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11:58–65. doi: 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
- 33.De Battista C, Solvason HB, Heilig Breen JA, et al. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 2000;20:274–275. doi: 10.1097/00004714-200004000-00029. [DOI] [PubMed] [Google Scholar]
- 34.Mayeux R, Stern Y, Cote L, et al. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology. 1984;34:642–646. doi: 10.1212/WNL.34.5.642. [DOI] [PubMed] [Google Scholar]
- 35.Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605–8. doi: 10.1038/33416. [DOI] [PubMed] [Google Scholar]
- 36.D'Souza T, Rajkumar A. Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson's disease. Acta Neuropsychiatrica. 2020;32(1):10–22. doi: 10.1017/neu.2019.28</underline>. [DOI] [PubMed] [Google Scholar]
- 37.Jo S, Kim SO, Park KW, et al. The role of APOE in cognitive trajectories and motor decline in Parkinson's disease. Sci Rep. 2021;11(1):7819. doi: 10.1038/s41598-021-86483-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Herbert J, Ban M, Brown GW, et al. Interaction between the BDNF gene Val/66/Met polymorphism and morning cortisol levels as a predictor of depression in adult women. Br J Psychiatry. 2012;201(4):313–9. doi: 10.1192/bjp.bp.111.107037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Chakraborty A, Diwan A. A genetic abnormalities behind the PD, and its therapeutic intervention. Neurol Curr Res. 2022;2(1):1012. [Google Scholar]
- 40.Levinson DF. The Genetics of Depression: A Review. Biol Psychiat. 2006;60(2):84–92. doi: 10.1016/j.biopsych.2005.08.024. [DOI] [PubMed] [Google Scholar]
- 41.Sia M-W, Foo J-N, Saffari S-E, et al. Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort. Movement Disord. 2021;36(12):2936–2940. doi: 10.1002/mds.28761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Maria S, Bondarenko EA, Slominsky PA. Genetics factors in major depression disease. Front Psychiatry. 2018;9:334. doi: 10.3389/fpsyt.2018.00334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80:2035. doi: 10.1212/WNL.0b013e318294b3c8. [DOI] [PubMed] [Google Scholar]
- 44.Gamache P-L, Roux-Dubois N, Provencher P, et al. Professional exposure to pesticides and heavy metals hastens Parkinson Disease onset (P6.008) Neurology. 2017;88:P6.008. [Google Scholar]
- 45.Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol. 2009;66:494–504. doi: 10.1002/ana.21717. [DOI] [PubMed] [Google Scholar]
- 46.Pouchieu C, Piel C, Carles C, et al. Pesticide use in agriculture and Parkinson's disease in the AGRICAN cohort study. Int J Epidemiol. 2018;47:299–310. doi: 10.1093/ije/dyx225. [DOI] [PubMed] [Google Scholar]
- 47.Castillo S, Muñoz P, Behrens MI, et al. On the role of mining exposure in epigenetic effects in Parkinson's disease. Neurotox Res. 2017;32:172–4. doi: 10.1007/s12640-017-9736-7. [DOI] [PubMed] [Google Scholar]
- 48.Willis AW, Evanoff BA, Lian M, et al. Metal emissions and urban incident Parkinson disease: a community health study of medicare beneficiaries by using geographic information systems. Am J Epidemiol. 2010;172:1357–63. doi: 10.1093/aje/kwq303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Palacios N. Air pollution and Parkinson's disease – evidence and future directions. Rev Environ Health. 2017;32:303–13. doi: 10.1515/reveh-2017-0009. [DOI] [PubMed] [Google Scholar]
- 50.Ritz B, Lee P-C, Hansen J, et al. Traffic-related air pollution and Parkinson's disease in Denmark: a case–control study. Environ Health Perspect. 2016;124:351–6. doi: 10.1289/ehp.1409313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Finkelstein MM, Jerrett M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res. 2007;104:420–32. doi: 10.1016/j.envres.2007.03.002. [DOI] [PubMed] [Google Scholar]
- 52.Todd G, Pearson-Dennett V, Wilcox RA, et al. Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism. Parkinsonism Relat Disord. 2016;25:27–32. doi: 10.1016/j.parkreldis.2016.02.019. [DOI] [PubMed] [Google Scholar]
- 53.Todd G, Noyes C, Flavel SC, et al. Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS ONE. 2013;8:e56438. doi: 10.1371/journal.pone.0056438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Mursaleen LR, Stamford JA. Drugs of abuse and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:209–17. doi: 10.1016/j.pnpbp.2015.03.013. [DOI] [PubMed] [Google Scholar]
- 55.Remes O, Mendes JF, Templeton P. Biological, Psychological, and Social Determinants of Depression: A Review of Recent Literature. Brain Sci. 2021;11(12):1633. doi: 10.3390/brainsci11121633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Schrempft S, Jackowska M, Hamer M, et al. Associations between social isolation, loneliness, and objective physical activity in older men and women. BMC Public Health. 2019;19:74. doi: 10.1186/s12889-019-6424-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Depression. Parkinson's Foundation. Available from: https://www.parkinson.org›non-movement-symptoms.
- 58.Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand. 2006;113(4):211–20. doi: 10.1111/j.1600-0404.2006.00579.x. [DOI] [PubMed] [Google Scholar]
- 59.NIH: National Institute of Mental Health. Depression. Available from: https://www.nimh.nih.gov/health/publications/depression.
- 60.Parkinson's Foundation. Depression. https://www.parkinson.org/understanding-parkinsons/symptoms/non-movement-symptoms/depression.
- 61.Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord. 2003;18(4):414–8. doi: 10.1002/mds.10387. [DOI] [PubMed] [Google Scholar]
- 62.Looi JC, Matis M, Ruzich MJ. Conceptualization of depression in Parkinson's disease. Neuropsychiatr Dis Treat. 2005;1(2):135–43. doi: 10.2147/nedt.1.2.135.61051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Anand A, Charney DS. Norepinephrine dysfunction in depression. J Clin Psychiatry. 2000;61(Suppl 10):16–24. [PubMed] [Google Scholar]
- 64.American Parkinson Disease Association. Depression in Parkinson's. [Accessed 12/20/2021]. Available from: https://www.apdaparkinson.org/what-is parkinsons/symptoms/depression/
- 65.American Parkinson Disease Association. Depression and Parkinson's disease. [Accessed 12/20/2021]. Available from: https://d2icp22po6iej.cloudfront.net/wp-content/uploads/2017/02/APDA1709-Supplement-Depression-D4V1.pdf.
- 66.Marsh L. Depression and Parkinson's disease: current knowledge. Curr Neurol Neurosci Rep. 2013;13:409. doi: 10.1007/s11910-013-0409-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Michael J. Fox Foundation for Parkinson's Research. Depression and Anxiety. [Accessed 12/20/2021]. Available from: https://www.michaeljfox.org/news/depression-anxiety.
- 68.Parkinson's Foundation. Depression. [Accessed 12/20/2021]. Available from: https://www.parkinson.org/Understanding-Parkinsons/Symptoms/Non-Movement-Symptoms/Depression.
- 69.Mayeux R, Stern Y, Williams JBW, et al. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry. 1986;43:756–9. doi: 10.1176/ajp.143.6.756. [DOI] [PubMed] [Google Scholar]
- 70.Kostic VS, Djuricic BM, Covickovic-Sternic N, et al. Depression and Parkinson's disease: possible role of serotonergic mechanisms. J Neurol. 1987;234:94–96. doi: 10.1007/BF00314109. [DOI] [PubMed] [Google Scholar]
- 71.Placebo study. Imipramine in Treatment of Parkinsonism: a Double-blind Placebo Study. Br BMJ. 1965;2(5452):33–34. doi: 10.1136/bmj.2.5452.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurol Scand. 1969;45(1):109–113. doi: 10.1111/j.1600-0404.1969.tb01224.x. [DOI] [PubMed] [Google Scholar]
- 73.Anderson J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand. 1980;62(4):210–19. doi: 10.1111/j.1600-0404.1980.tb03028.x. [DOI] [PubMed] [Google Scholar]
- 74.Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology. 1984;34:1092–1094. doi: 10.1212/WNL.34.8.1092. [DOI] [PubMed] [Google Scholar]
- 75.Klaassen T, Verhey FRJ, Sneijders GHJ, et al. Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci. 1995;7:281–286. doi: 10.1176/jnp.7.3.281. [DOI] [PubMed] [Google Scholar]

